Holen Sie sich die Stockscreener-App
3.11
0.65%
0.02
Schlusskurs vom Vortag:
$3.09
Offen:
$3.06
24-Stunden-Volumen:
16,111
Relative Volume:
0.39
Marktkapitalisierung:
$17.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-1.0197
EPS:
-3.05
Netto-Cashflow:
$-11.88M
1W Leistung:
-5.18%
1M Leistung:
+22.92%
6M Leistung:
-2.81%
1J Leistung:
-36.66%
1-Tages-Spanne:
$2.98
$3.149
1-Wochen-Bereich:
$2.98
$3.4499
52-Wochen-Spanne:
$2.52
$5.50
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Vergleichen Sie LPCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.11 | 17.16M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
| 2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
Lipocine Inc. (LPCN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN
Why hedge funds are buying Lipocine Inc. stockPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Can Lipocine Inc. stock sustain revenue growthJuly 2025 Weekly Recap & Community Consensus Stock Picks - newser.com
Will Lipocine Inc. stock outperform value stocksMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Can Lipocine Inc. stock resist sector downturnsJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
How Lipocine Inc. stock reacts to inflationary pressuresOptions Play & Free Growth Oriented Trading Recommendations - newser.com
Smart tools for monitoring Lipocine Inc.’s price actionEarnings Summary Report & Community Driven Trade Alerts - newser.com
Is Lipocine Inc. stock a safe buy before earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Lipocine reports positive safety review for PPD treatment in phase 3 trial - Investing.com Nigeria
Lipocine Announces Positive Interim Results for PPD Trial - TipRanks
[8-K] Lipocine Inc. Reports Material Event | LPCN SEC FilingForm 8-K - Stock Titan
Lipocine highlights promising interim safety profile in phase 3 trial of LPCN 1154 in postpartum depression (PPD) - MarketScreener
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - The Herald Journal
HC Wainwright Issues Negative Forecast for Lipocine Earnings - Defense World
Will Lipocine Inc. stock go up soonForecast Cut & Long-Term Growth Plans - newser.com
HC Wainwright Cuts Lipocine (NASDAQ:LPCN) Price Target to $7.00 - Defense World
Why analysts upgrade Lipocine Inc. stockJuly 2025 Earnings & Entry and Exit Point Strategies - newser.com
Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN
How Lipocine Inc. stock performs after earningsDollar Strength & Growth Oriented Trade Recommendations - newser.com
Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline - Investing.com Nigeria
Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline By Investing.com - Investing.com South Africa
LPCN: Analyst Lowers Price Target While Maintaining Buy Rating | - GuruFocus
Will a bounce in Lipocine Inc. offer an exitEarnings Risk Report & Weekly Watchlist for Consistent Profits - newser.com
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):